Hepatic macrophages in homeostasis and liver diseases: From pathogenesis to novel therapeutic strategies

Cellular and Molecular Immunology

Volumn 13, Issue 3, 2016, Pages 316-327

  Ju, Cynthia ^a   Tacke, Frank ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

chemokine; liver fibrosis; macrophage; microbiome; monocyte

Indexed keywords

CONCANAVALIN A; PARACETAMOL;

ALCOHOL LIVER DISEASE; BONE MARROW DERIVED MACROPHAGE; BONE MARROW DERIVED MONOCYTE; CELLS BY BODY ANATOMY; HEPATITIS; HOMEOSTASIS; HUMAN; INFLAMMATORY DISEASE; INNATE IMMUNITY; KUPFFER CELL; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; LIVER INJURY; LIVER ISCHEMIA; LIVER MACROPHAGE; LIVER TOXICITY; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; REVIEW; VIRUS HEPATITIS; ANIMAL; LIVER; LIVER DISEASES; PATHOLOGY;

ANIMALS; HOMEOSTASIS; HUMANS; LIVER; LIVER DISEASES; MACROPHAGES;

EID: 84966297002     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2015.104     Document Type: Review

References (136)

1. Varol C, Mildner A, Jung S. Macrophages: development and tissue specialization. Annu Rev Immunol 2015; 33: 643-675.
2. Tacke F, Zimmermann HW. Macrophage heterogeneity in liver injury and fibrosis. J Hepatol 2014; 60: 1090-1096.
3. Lavin Y, Winter D, Blecher-Gonen R, David E, Keren-Shaul H, Merad M et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 2014; 159: 1312-1326.
4. Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 2014; 40: 274-288.
5. Dal-Secco D, Wang J, Zeng Z, Kolaczkowska E, Wong CH, Petri B et al. A dynamic spectrum of monocytes arising from the in situ reprogramming of CCR21 monocytes at a site of sterile injury. J Exp Med 2015; 212: 447-456.
6. Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. Immunity 2014; 41: 21-35.
7. Karlmark KR, Weiskirchen R, Zimmermann HW, Gassler N, Ginhoux F, Weber C et al. Hepatic recruitment of the inflammatory Gr11 monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 2009; 50: 261-274.
8. Gomez PE, Klapproth K, Schulz C, Busch K, Azzoni E, Crozet L et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 2015; 518: 547-551.
9. Yona S, Kim KW, Wolf Y, Mildner A, Varol D, Breker M et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 2013; 38: 79-91.
10. Schulz C, Gomez PE, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 2012; 336: 86-90.
11. Heymann F, Peusquens J, Ludwig-Portugall I, Kohlhepp M, Ergen C, Niemietz P et al. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology 2015; 62: 279-291.
12. Antoniades CG, Quaglia A, Taams LS, Mitry RR, Hussain M, AbelesR et al. Source and characterization of hepatic macrophages in acetaminophen-induced acute liver failure in humans. Hepatology 2012; 56: 735-746.
13. Gonzalez-Dominguez E, Samaniego R, Flores-Sevilla JL, Campos- Campos SF, Gómez-Campos G, Salas A et al. CD163L1 and CLEC5A discriminate subsets of human resident and inflammatory macrophages in vivo. J Leukoc Biol 2015; 98: 453-466.
14. Tacke F, Randolph GJ. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 2006; 211: 609-618.
15. Ingersoll MA, Spanbroek R, Lottaz C, Gautier EL, Frankenberger M, Hoffmann R et al. Comparison of gene expression profiles between human and mouse monocyte subsets. Blood 2010; 115: e10-e19.
16. Carlin LM, Auffray C, Geissmann F. Measuring intravascular migration of mouse Ly6C(low) monocytes in vivo using intravital microscopy. Curr Protoc Immunol 2013; Chapter 14:Unit 14. 33. 1-16.
17. Carlin LM, Stamatiades EG, Auffray C, Hanna RN, Glover L, Vizcay- Barrena G et al. Nr4a1-dependent Ly6C(low) monocytes monitor endothelial cells and orchestrate their disposal. Cell 2013; 153: 362-375.
18. Collison JL, Carlin LM, Eichmann M, Geissmann F, Peakman M. Heterogeneity in the locomotory behavior of human monocyte subsets over human vascular endothelium in vitro. J Immunol 2015; 195: 1162-1170.
19. Heymann F, Hammerich L, Storch D, Bartneck M, Huss S, Rüsseler V et al. Hepatic macrophage migration and differentiation critical for liver fibrosis is mediated by the chemokine receptor C-C motif chemokine receptor 8 in mice. Hepatology 2012; 55: 898-909.
20. Ramachandran P, Pellicoro A, Vernon MA, Boulter L, Aucott RL, Ali A et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci U S A 2012; 109: E3186-E3195.
21. You Q, Holt M, Yin H, Li G, Hu CJ, Ju C. Role of hepatic resident and infiltrating macrophages in liver repair after acute injury. Biochem Pharmacol 2013; 86: 836-843.
22. Liaskou E, Zimmermann HW, Li KK, Oo YH, Suresh S, Stamataki Z et al. Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics. Hepatology 2013; 57: 385-398.
23. Zimmermann HW, Seidler S, Nattermann J, Nikolaus Gassler, Claus Hellerbrand, Alma Zernecke et al. Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One 2010; 5: e11049.
24. Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol 2013; 14: 996-1006.
25. Knolle P, Schlaak J, Uhrig A, Kempf P, Meyer zum Büschenfelde KH, Gerken G. Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. J Hepatol 1995; 22: 226-229.
26. You Q, Cheng L, Kedl RM, Ju C. Mechanism of T cell tolerance induction by murine hepatic Kupffer cells. Hepatology 2008; 48: 978-990.
27. Yan ML, Wang YD, Tian YF, Lai ZD, Yan LN. Inhibition of allogeneic T-cell response by Kupffer cells expressing indoleamine 2, 3- dioxygenase. World J Gastroenterol 2010; 16: 636-640.
28. Elsegood CL, Chan CW, Degli-Esposti MA, Wikstrom ME, Domenichini A, Lazarus K et al. Kupffer cell-monocyte communication is essential for initiating murine liver progenitor cell-mediated liver regeneration. Hepatology 2015; 62: 1272-1284.
29. Seki E, De MS, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13: 1324-1332.
30. Melgar-Lesmes P, Edelman ER. Monocyte-endothelial cell interactions in the regulation of vascular sprouting and liver regeneration in mouse. J Hepatol 2015; 63: 917-925.
31. Ehling J, Bartneck M, Wei X, Gremse F, Fech V, Möckel D et al. CCL2- dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut 2014; 63: 1960-1971.
32. Movita D, van de Garde MD, Biesta P, Kim Kreefft, Bart Haagmans, Elina Zuniga et al. Inflammatory monocytes recruited to the liver within 24 hours after virus-induced inflammation resemble Kupffer cells but are functionally distinct. J Virol 2015; 89: 4809-4817.
33. Zigmond E, Samia-Grinberg S, Pasmanik-Chor M, Brazowski E, Shibolet O, Halpern Z et al. Infiltrating monocyte-derived macrophages and resident kupffer cells display different ontogeny and functions in acute liver injury. J Immunol 2014; 193: 344-353.
34. Holt MP, Cheng L, Ju C. Identification and characterization of infiltrating macrophages in acetaminophen-induced liver injury. J Leukoc Biol 2008; 84: 1410-1421.
35. Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, van Rooijen N et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 2011; 332: 1284-1288.
36. Laskin DL, Gardner CR, Price VF, Jollow DJ. Modulation of macrophage functioning abrogates the acute hepatotoxicity of acetaminophen. Hepatology 1995; 21: 1045-1050.
37. Michael SL, Pumford NR, Mayeux PR, Niesman MR, Hinson JA. Pretreatment of mice with macrophage inactivators decreases acetaminophen hepatotoxicity and the formation of reactive oxygen and nitrogen species. Hepatology 1999; 30: 186-195.
38. Bourdi M, Masubuchi Y, Reilly TP, Amouzadeh HR, Martin JL, George JW et al. Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. Hepatology 2002; 35: 289-298.
39. Ryan PM, Bourdi M, Korrapati MC, Proctor WR, Vasquez RA, Yee SB et al. Endogenous interleukin-4 regulates glutathione synthesis following acetaminophen-induced liver injury in mice. Chem Res Toxicol 2012; 25: 83-93.
40. Yee SB, Bourdi M, Masson MJ, Pohl LR. Hepatoprotective role of endogenous interleukin-13 in a murine model of acetaminopheninduced liver disease. Chem Res Toxicol 2007; 20: 734-744.
41. Campion SN, Johnson R, Aleksunes LM, Goedken MJ, van Rooijen N, Scheffer GL et al. Hepatic Mrp4 induction following acetaminophen exposure is dependent on Kupffer cell function. Am J Physiol Gastrointest Liver Physiol 2008; 295: G294-G304.
42. Ju C, Reilly TP, Bourdi M, Radonovich MF, Brady JN, George JW et al. Protective role of Kupffer cells in acetaminophen-induced hepatic injury in mice. Chem Res Toxicol 2002; 15: 1504-1513.
43. Stutchfield BM, Antoine DJ, Mackinnon AC, Gow DJ, Bain CC, Hawley CA et al. CSF1 Restores innate immunity after liver injury in mice and serum levels indicate outcomes of patients with acute liver failure. Gastroenterology 2015; 149: 1896-1909. e14
44. Morita A, Itoh Y, Toyama T, Fujii H, Nishioji K, Kirishima T et al. Activated Kupffer cells play an important role in intra-hepatic Th1- associated necro-inflammation in Concanavalin A-induced hepatic injury in mice. Hepatol Res 2003; 27: 143-150.
45. Schumann J, Wolf D, Pahl A, Brune K, Papadopoulos T, van Rooijen N et al. Importance of Kupffer cells for T-cell-dependent liver injury in mice. Am J Pathol 2000; 157: 1671-1683.
46. Chen L, Xie XJ, Ye YF, Zhou L, Xie HY, Xie QF et al. Kupffer cells contribute to concanavalin A-induced hepatic injury through a Th1 but not Th17 type response-dependent pathway in mice. Hepatobiliary Pancreat Dis Int 2011; 10: 171-178.
47. Erhardt A, Biburger M, Papadopoulos T, Tiegs G. IL-10, regulatory T cells, and Kupffer cells mediate tolerance in concanavalin Ainduced liver injury in mice. Hepatology 2007; 45: 475-485.
48. Erhardt A, Tiegs G. Tolerance induction in response to liver inflammation. Dig Dis 2010; 28: 86-92.
49. Howard TK, Klintmalm GB, Cofer JB, Husberg BS, Goldstein RM, Gonwa TA. The influence of preservation injury on rejection in the hepatic transplant recipient. Transplantation 1990; 49: 103-107.
50. Abu-Amara M, Yang SY, Tapuria N, Fuller B, Davidson B, Seifalian A. Liver ischemia/reperfusion injury: processes in inflammatory networks-a review. Liver Transpl 2010; 16: 1016-1032.
51. Hardonk MJ, Dijkhuis FW, Hulstaert CE, Koudstaal J. Heterogeneity of rat liver and spleen macrophages in gadolinium chloride-induced elimination and repopulation. J Leukoc Biol 1992; 52: 296-302.
52. Giakoustidis DE, Iliadis S, Tsantilas D, Papageorgiou G, Kontos N, Kostopoulou E et al. Blockade of Kupffer cells by gadolinium chloride reduces lipid peroxidation and protects liver from ischemia/reperfusion injury. Hepatogastroenterology 2003; 50: 1587-1592.
53. Tomiyama K, Ikeda A, Ueki S, Nakao A, Stolz DB, Koike Y et al. Inhibition of Kupffer cell-mediated early proinflammatory response with carbon monoxide in transplant-induced hepatic ischemia/ reperfusion injury in rats. Hepatology 2008; 48: 1608-1620.
54. Ellett JD, Atkinson C, Evans ZP, Amani Z, Balish E, Schmidt MG et al. Murine Kupffer cells are protective in total hepatic ischemia/ reperfusion injury with bowel congestion through IL-10. J Immunol 2010; 184: 5849-5858.
55. Bamboat ZM, Ocuin LM, Balachandran VP, Obaid H, Plitas G, DeMatteo RP. Conventional DCs reduce liver ischemia/reperfusion injury in mice via IL-10 secretion. J Clin Invest 2010; 120: 559-569.
56. Richards JA, Wigmore SJ, Devey LR. Heme oxygenase system in hepatic ischemia-reperfusion injury. World J Gastroenterol. 2010; 16: 6068-6078.
57. Zhai Y, Busuttil RW, Kupiec-Weglinski JW. Liver ischemia and reperfusion injury: new insights into mechanisms of innateadaptive immune-mediated tissue inflammation. Am J Transplant 2011; 11: 1563-1569.
58. Helk E, Bernin H, Ernst T, Jacobs T, Heeren J, Tacke F et al. TNFalpha-mediated liver destruction by Kupffer cells and Ly6Chi monocytes during Entamoeba histolytica infection. PLoS Pathog 2013; 9: e1003096.
59. Morias Y, Abels C, Laoui D, Guilliams M, Schouppe E, Tacke F et al. Ly6C- Monocytes Regulate Parasite-Induced Liver Inflammation by Inducing the Differentiation of Pathogenic Ly6C1 Monocytes into Macrophages. PLoS Pathog 2015; 11: e1004873.
60. Karakucuk I, Dilly SA, Maxwell JD. Portal tract macrophages are increased in alcoholic liver disease. Histopathology 1989; 14: 245-253.
61. Tapia-Abellan A, Martinez-Esparza M, Ruiz-Alcaraz AJ, Hernández- Caselles T, Martínez-Pascual C, Miras-López M et al. The peritoneal macrophage inflammatory profile in cirrhosis depends on the alcoholic or hepatitis C viral etiology and is related to ERK phosphorylation. BMC Immunol 2012; 13: 42.
62. Lee J, French B, Morgan T, French SW. The liver is populated by a broad spectrum of markers for macrophages. In alcoholic hepatitis the macrophages are M1 and M2. Exp Mol Pathol 2014; 96: 118-125.
63. Luna-Casado L, Diez-Ruiz A, Gutierrez-Gea F, Santos-Perez JL, Rico-Irles J, Wachter H et al. Increased peripheral mononuclear cells expression of adhesion molecules in alcoholic cirrhosis: its relation to immune activation. J Hepatol 1997; 27: 477-483.
64. Afford SC, Fisher NC, Neil DA, Fear J, Brun P, Hubscher SG et al. Distinct patterns of chemokine expression are associated with leukocyte recruitment in alcoholic hepatitis and alcoholic cirrhosis. J Pathol 1998; 186: 82-89.
65. Fisher NC, Neil DA, Williams A, Adams DH. Serum concentrations and peripheral secretion of the beta chemokines monocyte chemoattractant protein 1 and macrophage inflammatory protein 1alpha in alcoholic liver disease. Gut 1999; 45: 416-420.
66. McClain CJ, Barve S, Deaciuc I, Kugelmas M, Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis 1999; 19: 205-219.
67. Gobejishvili L, Barve S, Joshi-Barve S, Uriarte S, Song Z, McClain C. Chronic ethanol-mediated decrease in cAMP primes macrophages to enhanced LPS-inducible NF-kappaB activity and TNF expression: relevance to alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2006; 291: G681-G688.
68. Zhang Z, Bagby GJ, Stoltz D, Oliver P, Schwarzenberger PO, Kolls JK. Prolonged ethanol treatment enhances lipopolysaccharide/phorbol myristate acetate-induced tumor necrosis factor-alpha production in human monocytic cells. Alcohol Clin Exp Res 2001; 25: 444-449.
69. Enomoto N, Ikejima K, Bradford BU, Rivera CA, Kono H, Goto M et al. Role of Kupffer cells and gut-derived endotoxins in alcoholic liver injury. J Gastroenterol Hepatol 2000;15 Suppl: D20-D25.
70. Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest 2012; 122: 3476-3489.
71. Koop DR, Klopfenstein B, Iimuro Y, Thurman RG. Gadolinium chloride blocks alcohol-dependent liver toxicity in rats treated chronically with intragastric alcohol despite the induction of CYP2E1. Mol Pharmacol 1997; 51: 944-950.
72. Mandrekar P, Ambade A, Lim A, Szabo G, Catalano D. An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice. Hepatology 2011; 54: 2185-2197.
73. Nagy LE. Recent insights into the role of the innate immune system in the development of alcoholic liver disease. Exp Biol Med (Maywood) 2003; 228: 882-890.
74. Wang M, You Q, Lor K, Chen F, Gao B, Ju C. Chronic alcohol ingestion modulates hepatic macrophage populations and functions in mice. J Leukoc Biol 2014; 96: 657-665.
75. Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390-1397.
76. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129.
77. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
78. Tu Z, Pierce RH, Kurtis J, Kuroki Y, Crispe IN, Orloff MS. Hepatitis C virus core protein subverts the antiviral activities of human Kupffer cells. Gastroenterology 2010; 138: 305-314.
79. Chang S, Dolganiuc A, Szabo G. Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins. J Leukoc Biol 2007; 82: 479-487.
80. Hosomura N, Kono H, Tsuchiya M, Ishii K, Ogiku M, Matsuda M et al. HCV-related proteins activate Kupffer cells isolated from human liver tissues. Dig Dis Sci 2011; 56: 1057-1064.
81. Khakoo SI, Soni PN, Savage K, Brown D, Dhillon AP, Poulter LW et al. Lymphocyte and macrophage phenotypes in chronic hepatitis C infection. Correlation with disease activity. Am J Pathol 1997; 150: 963-970.
82. McGuinness PH, Painter D, Davies S, McCaughan GW. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut 2000; 46: 260-269.
83. Burgio VL, Ballardini G, Artini M, Caratozzolo M, Bianchi FB, Levrero M. Expression of co-stimulatory molecules by Kupffer cells in chronic hepatitis of hepatitis C virus etiology. Hepatology 1998; 27: 1600-1606.
84. Dolganiuc A, Norkina O, Kodys K, Catalano D, Bakis G, Marshall C et al. Viral and host factors induce macrophage activation and loss of toll- l ike receptor tolerance in chronic HCV infection. Gastroenterology 2007; 133: 1627-1636.
85. Shrivastava S, Mukherjee A, Ray R, Ray RB. Hepatitis C virus induces interleukin-1beta (IL-1beta)/IL-18 in circulatory and resident liver macrophages. J Virol 2013; 87: 12284-12290.
86. Boltjes A, Movita D, Boonstra A, Woltman AM. The role of Kupffer cells in hepatitis B and hepatitis C virus infections. J Hepatol 2014; 61: 660-671.
87. Broering R, Wu J, Meng Z, Hilgard P, Lu M, Trippler M et al. Toll-like receptor-stimulated non-parenchymal liver cells can regulate hepatitis C virus replication. J Hepatol 2008; 48: 914-922.
88. Zhu H, Liu C. Interleukin-1 inhibits hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinase pathway. J Virol 2003; 77: 5493-5498.
89. Zhu H, Shang X, Terada N, Liu C. STAT3 induces anti-hepatitis C viral activity in liver cells. Biochem Biophys Res Commun 2004; 324: 518-528.
90. Tordjmann T, Soulie A, Guettier C, Schmidt M, Berthou C, Beaugrand M et al. Perforin and granzyme B lytic protein expression during chronic viral and autoimmune hepatitis. Liver 1998; 18: 391-397.
91. Tang TJ, Kwekkeboom J, Laman JD, Niesters HG, Zondervan PE, de Man RA et al. The role of intrahepatic immune effector cells in inflammatory liver injury and viral control during chronic hepatitis B infection. J Viral Hepat 2003; 10: 159-167.
92. Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol 2006; 12: 7413-7420.
93. Chang S, Dolganiuc A, Szabo G. Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins. J Leukoc Biol 2007; 82: 479-487.
94. Li H, Zheng HW, Chen H, Xing ZZ, You H, Cong M et al. Hepatitis B virus particles preferably induce Kupffer cells to produce TGF-beta1 over pro-inflammatory cytokines. Dig Liver Dis 2012; 44: 328-333.
95. Mengshol JA, Golden-Mason L, Arikawa T, Smith M, Niki T, McWilliams R et al. A crucial role for Kupffer cell-derived galectin-in regulation of T cell immunity in hepatitis C infection. PLoS One 2010; 5: e9504.
96. Sandler NG, Koh C, Roque A, Smith M, Niki T, McWilliams R et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011; 141: 1220-1230.
97. Nebbia G, Peppa D, Schurich A, Khanna P, Singh HD, Cheng Y et al. Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One 2012; 7: e47648.
98. Wallace K, Burt AD, Wright MC. Liver fibrosis. Biochem J 2008; 411: 1-18.
99. Pradere JP, Kluwe J, De MS, Jiao JJ, Gwak GY, Dapito DH et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology 2013; 58: 1461-1473.
100. Fallowfield JA, Mizuno M, Kendall TJ, Constandinou CM, Benyon RC, Duffield JS et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol 2007; 178: 5288-5295.
101. Pellicoro A, Aucott RL, Ramachandran P, Robson AJ, Fallowfield JA, Snowdon VK et al. Elastin accumulation is regulated at the level of degradation by macrophage metalloelastase (MMP-12) during experimental liver fibrosis. Hepatology 2012; 55: 1965-1975.
102. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005; 115: 56-65.
103. Baeck C, Wehr A, Karlmark KR, Heymann F, Vucur M, Gassler N et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 2012; 61: 416-426.
104. Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int 2013; 2013: 187204.
105. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317: 121-124.
106. Wu J, Li J, Salcedo R, Mivechi NF, Trinchieri G, Horuzsko A. The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. Cancer Res 2012; 72: 3977-3986.
107. Wan S, Zhao E, Kryczek I, Mivechi NF, Trinchieri G, Horuzsko A. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology 2014; 147: 1393-1404.
108. Wu K, Kryczek I, Chen L, Zou W, Welling TH. Kupffer cell suppression of CD81 T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res 2009; 69: 8067-8075.
109. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 2009; 206: 1327-1337.
110. Ding T, Xu J, Wang F, Shi M, Zhang Y, Li S-P et al. High tumorinfiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum Pathol 2009; 40: 381-389.
111. Ikeda M, Ohkawa S, Okusaka T, Mitsunaga S, Kobayashi S, Morizane C et al. Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma. Cancer Sci 2014; 105: 455-462.
112. Zhu AX, Gold PJ, El-Khoueiry AB, Abrams TA, Morikawa H, Ohishi N et al. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2013; 19: 920-928.
113. Rogers TL, Wind N, Hughes R, Nutter F, Brown HK, Vasiliadou I et al. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models. Cell Oncol (Dordr. ) 2013; 36: 505-514.
114. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 2010; 14: 2803-2815.
115. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014; 146: 1513-1524.
116. Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014; 513: 59-64.
117. Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012; 21: 504-516.
118. Mazagova M, Wang L, Anfora AT, Wissmueller M, Lesley SA, Miyamoto Y et al. Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. FASEB J 2015; 29: 1043-1055.
119. Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology 2014; 147: 577-594.
120. Baeck C, Wei X, Bartneck M, Fech V, Heymann F, Gassler N et al. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(1) macrophage infiltration in mice. Hepatology 2014; 59: 1060-1072.
121. Preisser L, Miot C, Le Guillou-Guillemette H, Beaumont E, Foucher ED, Garo E et al. IL-34 and macrophage colony-stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells. Hepatology 2014; 60: 1879-1890.
122. Kedarisetty CK, Anand L, Bhardwaj A, Bhadoria AS, Kumar G, Vyas AK et al. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis. Gastroenterology 2015; 148: 1362-1370.
123. Bartneck M, Warzecha KT, Tacke F. Therapeutic targeting of liver inflammation and fibrosis by nanomedicine. Hepatobiliary Surg Nutr 2014; 3: 364-376.
124. Liu T, Li L, Fu C, Liu H, Chen D, Tang F. Pathological mechanisms of liver injury caused by continuous intraperitoneal injection of silica nanoparticles. Biomaterials 2012; 33: 2399-2407.
125. Bartneck M, Ritz T, Keul HA, Wambach M, Bornemann J, GbureckU et al. Peptide-functionalized gold nanorods increase liver injury in hepatitis. ACS Nano 2012; 6: 8767-8777.
126. Bartneck M, Scheyda KM, Warzecha KT, Rizzo LY, Hittatiya K, Luedde T et al. Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases. Biomaterials 2015; 37: 367-382.
127. Bartneck M, Peters FM, Warzecha KT, Bienert M, van Bloois L, Trautwein C et al. Liposomal encapsulation of dexamethasone modulates cytotoxicity, inflammatory cytokine response, and migratory properties of pr imary human macrophages. Nanomedicine 2014; 10: 1209-1220.
128. Melgert BN, Olinga P, Van Der Laan JM, Weert B, Cho J, Schuppan D et al. Targeting dexamethasone to Kupffer cells: effects on liver inflammation and fibrosis in rats. Hepatology 2001; 34: 719-728.
129. He C, Yin L, Tang C, Yin C. Multifunctional polymeric nanoparticles for oral delivery of TNF-alpha siRNA to macrophages. Biomaterials 2013; 34: 2843-2854.
130. Hammerich L, Tacke F. Interleukins in chronic liver disease: lessons learned from experimental mouse models. Clin Exp Gastroenterol 2014; 7: 297-306.
131. Traber PG, Chou H, Zomer E, Hong F, Klyosov A, Fiel M-I et al. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One 2013; 8: e75361.
132. Traber PG, Zomer E. Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One 2013; 8: e83481.
133. Iredale JP, Bataller R. Identifying molecular factors that contribute to resolution of liver fibrosis. Gastroenterology 2014; 146: 1160-1164.
134. Tacke F, Trautwein C. Mechanisms of liver fibrosis resolution. J Hepatol 2015; 63: 1038-1039.
135. Thomas JA, Pope C, Wojtacha D, Robson AJ, Gordon-Walker TT, Hartland S et al. Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function. Hepatology 2011; 53: 2003-2015.
136. King A, Barton D, Beard HA, Ni Than N, Moore J, Corbett C et al. REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD1331 bone marrow stem cells in patients with cirrhosis. A study protocol for a randomised controlled trial. BMJ Open 2015; 5: e007700.